Biomarker Technologies Global Market Report 2026

Biomarker technologies refer to tools and analytical approaches used to identify and quantify biological markers within the body to understand health conditions and disease progression. These technologies analyze biological samples such as blood, tissue, urine, and saliva through genomics, proteomics, metabolomics, and molecular diagnostics methods. They help detect specific indicators associated with diseases, treatment effectiveness, and physiological changes.

The primary products of biomarker technologies include consumables, instruments, services, and software. Consumables refer to reagents, kits, and laboratory materials used in biomarker testing workflows for research and clinical applications. These products are used across test types including liquid biopsy and solid biopsy and are supported by technologies such as genomics, proteomics, metabolomics, immunoassays, and bioinformatics. They are widely applied in oncology, cardiology, neurology, infectious diseases, and metabolic disorders and are utilized by end users including pharmaceutical companies, diagnostic laboratories, research institutions, contract research organizations, and biotechnology companies.

Tariffs are influencing the biomarker technologies market by increasing the cost of imported laboratory instruments, sequencing platforms, reagents, assay kits, and other precision diagnostic components used in biomarker analysis. This is resulting in higher operational costs for diagnostic laboratories, pharmaceutical companies, and research institutions, while also delaying clinical validation and large-scale testing initiatives due to supply chain disruptions. Regions heavily dependent on imports, such as Asia-Pacific and parts of Europe, are experiencing significant cost pressures and project delays, particularly in genomics and proteomics workflows. However, tariffs are also accelerating localized manufacturing of diagnostic tools, supporting regional supplier ecosystems, and encouraging strategic sourcing diversification to build long-term resilience in the biomarker technologies market.

The biomarker technologies market research report is one of a series of new reports from The Business Research Company that provides biomarker technologies market statistics, including biomarker technologies industry global market size, regional shares, competitors with a biomarker technologies market share, detailed biomarker technologies market segments, market trends and opportunities, and any further data you may need to thrive in the biomarker technologies industry. This biomarker technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biomarker technologies market size has grown rapidly in recent years. It will grow from $56.62 billion in 2025 to $64.03 billion in 2026 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to increasing prevalence of chronic diseases driving diagnostic demand, expansion of clinical laboratory infrastructure globally, rising adoption of molecular diagnostic testing, growth in pharmaceutical R&D investments, improved awareness of early disease detection benefits.

The biomarker technologies market size is expected to see rapid growth in the next few years. It will grow to $103.12 billion in 2030 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to expansion of precision medicine adoption in healthcare systems, rising demand for minimally invasive diagnostic solutions, increasing integration of multi omics based research approaches, growth in decentralized and point of care testing models, expansion of personalized treatment monitoring and therapy optimization. Major trends in the forecast period include rising demand for early disease detection through molecular marker based screening, expansion of preventive and proactive healthcare screening programs, increasing regulatory standardization and validation requirements in diagnostic testing, growth of large scale biobanking and centralized biological sample repositories, rising adoption of multi sample biological testing workflows integrating blood urine and saliva based diagnostics.

The increasing demand for personalized medicine is expected to drive the growth of the biomarker technologies market going forward. Personalized medicine is a healthcare approach that utilizes genetic, molecular, and individual patient-specific information to support diagnosis, treatment selection, and disease management decisions. The demand for personalized medicine is rising as pharmaceutical companies increasingly focus on developing targeted therapies that require accurate patient identification and biomarker-driven treatment strategies. Biomarker technologies enable personalized medicine by identifying measurable biological indicators that support targeted drug development, patient segmentation, and treatment optimization. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients in 2023, representing a significant rise compared to six approvals in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the biomarker technologies market.

Major companies operating in the biomarker technologies market are focusing on developing advanced spatial biology technologies, such as artificial intelligence-enabled spatial biomarker analysis platforms, to enhance cancer diagnostics and translational research capabilities. Artificial intelligence-enabled spatial biomarker analysis platforms integrate tissue imaging, molecular profiling, and computational analytics to analyze biomarker expression patterns and cellular interactions within tissue samples. For instance, in April 2024, Nucleai, an Israel-based biotechnology company, launched new artificial intelligence-powered spatial biomarker advancements at the American Association for Cancer Research 2024 conference. The technology enables automated pathology analysis, combines spatial biology data with artificial intelligence models, and enhances biomarker discovery for oncology treatment development. The platform also facilitates detailed analysis of the tumor microenvironment, allowing researchers to better understand cellular interactions that impact disease progression and therapeutic response. Additionally, it supports patient stratification and predictive analytics, enabling pharmaceutical and biotechnology companies to identify appropriate patient groups and accelerate the development of personalized cancer treatments.

In July 2024, Thermo Fisher Scientific, a US-based provider of analytical instruments, acquired Olink Holding AB for $3.1 billion. Through this acquisition, Thermo Fisher Scientific aimed to enhance its proteomics and biomarker discovery capabilities by integrating Olink's advanced protein analysis platform to expand precision medicine and translational research applications. Olink Holding AB is a Sweden-based provider of proteomics solutions and biomarker discovery technologies that support disease research, pharmaceutical development, and precision diagnostics.

Major companies operating in the biomarker technologies market report are Labcorp Holdings Incorporated, Illumina Incorporated, BioMerieux SA, Bruker Corporation, Bio-Rad Laboratories Incorporated, Exact Sciences Corporation, Bio-Techne Corporation, Myriad Genetics Incorporated, MDxHealth SA, Guardant Health Incorporated, Veracyte Incorporated, Tempus AI Incorporated, Meso Scale Diagnostics LLC, Adaptive Biotechnologies Corporation, Alamar Biosciences Incorporated, Burning Rock Biotech Limited, SOPHiA GENETICS SA, Seer Incorporated, Biomodal Limited, Thermo Fisher Scientific, F. Hoffmann-La Roche AG, QIAGEN N.V., Agilent Technologies Incorporated, Quest Diagnostics Incorporated

North America was the dominating region in the biomarker technologies market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the biomarker technologies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the biomarker technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The biomarker technologies market consists of revenues earned by entities by providing services such as biomarker discovery services, molecular diagnostics services, genomic and proteomic analysis services, companion diagnostics services, biomarker validation services, and clinical research testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The biomarker technologies market also includes sales of biomarker assay kits, biosensors, sequencing instruments, chromatography systems, mass spectrometry instruments, and molecular diagnostic devices. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities, including downstream manufacturers, wholesalers, distributors, and retailers, or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biomarker Technologies Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses biomarker technologies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biomarker technologies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The biomarker technologies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product: Consumables; Instruments; Services; Software
• 2) By Test Type: Liquid Biopsy; Solid Biopsy
• 3) By Technology: Genomics; Proteomics; Metabolomics; Immunoassays; Bioinformatics
• 4) By Application: Oncology; Cardiology; Neurology; Infectious Diseases; Metabolic Disorders
• 5) By End User: Pharmaceutical Companies; Diagnostic Laboratories; Research Institutions; Contract Research Organizations; Biotechnology Companies
• Subsegments:
• 1) By Consumables: Reagents; Assay Kits; Antibodies; Buffers And Solutions; Sample Preparation Kits; Microarrays
• 2) By Instruments: Polymerase Chain Reaction Systems; Sequencing Instruments; Mass Spectrometers; Flow Cytometers; Imaging Systems; Chromatography Systems
• 3) By Services: Biomarker Discovery Services; Validation Services; Clinical Trial Services; Data Analysis Services; Sample Testing Services; Consulting Services
• 4) By Software: Bioinformatics Software; Data Management Software; Genomic Analysis Software; Proteomics Analysis Software; Clinical Data Interpretation Software; Artificial Intelligence Based Analytics Software
• Companies Mentioned: Labcorp Holdings Incorporated; Illumina Incorporated; BioMerieux SA; Bruker Corporation; Bio-Rad Laboratories Incorporated; Exact Sciences Corporation; Bio-Techne Corporation; Myriad Genetics Incorporated; MDxHealth SA; Guardant Health Incorporated; Veracyte Incorporated; Tempus AI Incorporated; Meso Scale Diagnostics LLC; Adaptive Biotechnologies Corporation; Alamar Biosciences Incorporated; Burning Rock Biotech Limited; SOPHiA GENETICS SA; Seer Incorporated; Biomodal Limited; Thermo Fisher Scientific; F. Hoffmann-La Roche AG; QIAGEN N.V.; Agilent Technologies Incorporated; Quest Diagnostics Incorporated
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.